Creative Medical Technology Holdings, Inc. - Common Stock (CELZ)
3.9000
+0.1400 (3.72%)
Creative Medical Technology Holdings Inc is a biotechnology company focused on the development of innovative medical therapies and treatments, particularly in the fields of regenerative medicine and cellular therapies
The company aims to transform healthcare through research and development of novel procedures and products that harness the body’s natural healing mechanisms. By leveraging advancements in cell-based treatments, Creative Medical Technology Holdings seeks to address a variety of medical conditions, providing solutions that enhance patient outcomes and quality of life. Through its commitment to scientific innovation, the company is dedicated to pioneering breakthroughs in medical technology.
Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQCELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.
PHOENIX, AZ / ACCESSWIRE / August 24, 2023 / Biotechnology company Creative Medical Technology Holdings, Inc. (NASDAQCELZ) seems to be witnessing success in the allogeneic cell therapy market.
Shares of HighPeak Energy, Inc. (NASDAQHPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results.
FDA approval under expanded access for Creative Medical. CELZ-201, a pioneering cell-based program, targets abnormal glucose tolerance to prevent Type 1 diabetes.
Creative Medical Technology Holdings, Inc., (NASDAQCELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals.
Creative Medical Technology Holdings, Inc. (NASDAQCELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelzTM. This cutting-edge therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals dealing with brittle Type 1 diabetes, a condition characterized by extreme fluctuations in blood glucose levels.
PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQCELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as AlloStem™. This study aims to determine the safety, efficacy and tolerability of CELZ-201-DDT, a proprietary, ready-to-use cell line developed by the company.
Creative Medical Technology Holdings, Inc. (NASDAQCELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as AlloStem™.
Gainers Avalo Therapeutics, Inc. (NASDAQAVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800 series.
